Salarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split HOUSTON, June 12, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop can…
Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split HOUSTON, June 12, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that it will effect a 1-for-8 reverse stock split at 5:00 p.m. Eastern Time, on June 14, 2024. Beginning with the opening of trading on June 17, 2024, Salarius' common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under a new CUSIP number 79400X404 and the Company's existing trading symbol “SLRX.”
SLRX Stock Earnings: Salarius Pharmaceuticals Beats EPS for Q1 2024 Salarius Pharmaceuticals (NASDAQ: SLRX ) just reported results for the first quarter of 2024. Salarius Pharmaceuticals reported earnings per share of -41 cents. This was above the analyst estimate for EPS of -$6.70. The company did not report any revenue for the quarter. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now. The post SLRX Stock Earnings: Salarius Pharmaceuticals Beats EPS for Q1 2024 appeared first on InvestorPlace .
SLRX Stock Earnings: Salarius Pharmaceuticals Beats EPS for Q4 2023 Salarius Pharmaceuticals (NASDAQ: SLRX ) just reported results for the fourth quarter of 2023. Salarius Pharmaceuticals reported earnings per share of -22 cents. This was above the analyst estimate for EPS of -$1.01. The company did not report any revenue for the quarter. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now.
Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Patient Enrollment Resumed in the Investigator-initiated Phase 1/2 Clinical Trial of Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers
Salarius Pharmaceuticals Announces Executive Restructuring and Cost-Saving Measures Salarius Pharmaceuticals Inc (SLRX) has released an update. Salarius Pharmaceuticals, Inc. has concluded a separation agreement with its CEO, David…
Salarius Pharmaceuticals Inc at Ladenburg Thalmann Healthcare Conference Transcript Salarius Pharmaceuticals Inc at Ladenburg Thalmann Healthcare Conference Transcript
Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals' Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment Additional Ewing Sarcoma Patient in Company's Phase 1/2 Sarcoma Trial Achieves Partial Response; Objective Response Rate Among First-Relapse Ewing Patients Treated with Seclidemstat, Topotecan and Cyclophosphamide Reaches 60% Additional Ewing Sarcoma Patient in Company's Phase 1/2 Sarcoma Trial Achieves Partial Response; Objective Response Rate Among First-Relapse Ewing Patients Treated with Seclidemstat, Topotecan and Cyclophosphamide Reaches 60%
Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program FDA briefing included new Ewing sarcoma clinical data from ongoing investigation where 60% of first-relapse patients achieved disease control and have not progressed after at least 14.5, 19.7 and 22.8 months
Short Interest in Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Declines By 26.4% … raised its position in Salarius Pharmaceuticals stock. Renaissance Technologies LLC … Latest Report on Salarius Pharmaceuticals Salarius Pharmaceuticals Company Profile (Get Free … #39; ratings for Salarius Pharmaceuticals and related companies with MarketBeat …